Lumbrokinase down-regulated the expression of BPTF and reduced the binding of BPTF at the VEGF promoter region, which in turn inhibited the transcription of VEGF and ultimately restrained tumor vascular prosperity and sensitized NSCLC to bevacizumab treatment. This evidence concerns the gene BPTF and neoplasm.